Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans.

Rech MA, Budde E, Evans CT, Finch D, Xia Y, Huo Z, Han JH. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. The American journal of emergency medicine. 2025 Jul 16; 97:97-102, DOI: 10.1016/j.ajem.2025.07.037.

Related HSR&D Project(s)

• RCS 20-192 – Research Career Scientist Award

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND AND OBJECTIVES: Two hemostatic agents are commonly used to reverse factor Xa (fXa) inhibitor-related intracranial hemorrhage (ICH): andexanet alfa (AA) or 4-factor prothrombin complex concentrate (4F-PCC). We sought evaluate real-world data in Veterans diagnosed with fXa inhibitor-related ICH by comparing short-term mortality and thrombotic events in patients who received AA vs. 4F-PCC. METHODS: This was a national retrospective cohort from the Veteran Health Administration of AA or 4 F-PCC between January 2018 to January 2024.The primary effectiveness endpoint was 90-day mortality. The primary safety endpoint was 30-day thrombotic events (venous thromboembolism, pulmonary embolism, acute ischemic stroke [AIS], myocardial infarction), validated through manual chart review. Propensity score-matched data set was first created to balance AA and 4F-PCC by the significant demographic and clinical variables and then was used to analyze and compare the results using the complete data set. RESULTS: Of 19,015 Veterans with ICH, 664 Veterans received AA (n  =  151) or 4F-PCC (n  =  513) and 350 Veterans received a fXa inhibitor (AA n  =  129; 4F-PCC n  =  221). 123 matched subjects were included in the propensity-matched cohort. The AA group was more likely to be on apixaban (AA group 87.8 % vs. 4F-PCC group 77.2 %, p  =  0.03). There was no difference in 90-day mortality between groups (30.9 % vs. 36.6 %, p  =  0.35). The AA group experienced significantly more 30-day thrombotic events compared to 4F-PCC (11.4 % vs. 2.4 %, p  <  0.01) and AIS was significantly more common with AA. CONCLUSION: In Veterans with fXa inhibitor-related ICH receiving AA or 4F-PCC, there was no difference in 90-day mortality. Consistent with previous literature from non-Veterans studies, 30-day thrombotic events were significantly higher in Veterans who received AA, including a significant increase in AIS. This study adds to the growing body of literature demonstrating higher thrombotic risks with AA. Selection of AA should be carefully weighed against the risk of thrombotic events.